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Summary.-The clinical usefulness of8 potential tumour markers has been evaluated
in 69 patients with Stage I and II breast cancer and 57 patients with Stage III and IV.
Serum CEA concentrations were raised in 13% ofpatients with local and 65% ofthose
with advanced breast cancer. In patients with clinical evidence of progression or
regression of tumour, serum CEA levels changed appropriately in 83% of cases.
Taking 4 of the markers (carcinoembryonic antigen (CEA), lactalbumin, o subunit
and haptoglobin) serum concentrations of one or more were raised in33% of patients
with local disease and 81% of those with advanced breast cancer. However, marker
concentrations were often only marginally raised, and are unlikely to provide a
sensitive guide to tumour burden. CEA, lactalbumin and a subunit were detectable
in 68%, 43% and 40% respectively of extracts of primary breast cancers.
ASSESSMENT of tumour burden remains reliably reflect tumour burden and that
a major problem in the management of
most patients with cancer. The measure-
ment of tumour products such as human
chorionic gonadotrophin (HCG) from
choriocarcinoma or calcitonin from medul-
lary carcinoma ofthe thyroid is invaluable
in the early diagnosis, monitoring of
therapy and detection of recurrence of
these tumours. For breast cancer a satis-
factory tumour marker or system of
tumour markers would be ofmajor clinical
importance at all stages ofthe disease, and
especially for early recognition of meta-
static disease.
Although no single sensitive marker has
so far been found for breast cancer,
abnormalities of one or more tumour-
related substances have been reported in
over 90% of patients with advanced
disease (Franchimont 3t al., 1976; Tormey
et al., 1975; Coombes et al., 1977). To
develop a multiparametric system for
monitoring breast cancer, it is necessary
to demonstrate that the components
abnormal levels are great enough and
frequent enough to be of clinical benefit.
The present study is an evaluation of
the clinical usefulness of 8 potential
tumour markers, selected because of re-
ported abnormal levels in breast cancer.
To define the relationship to tumour
burden, serum concentrations of each
potential marker were measured in
patients with local disease before and after
resection of primary disease, in patients
with advanced disease and in a control
population. In some patients, markers
were estimated before and after pro-
gression or regression of advanced breast
cancer. In addition, the proportion of
tumours synthesizing the markers was
defined by measuring the markers in ex-
tracts of primary breast tumours.
MATERIALS AND METHODS
Patient assessment and sample preparation.
-Serum concentrations of the potential
tumour markers were measured in 69 women
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before, and in 29 of these, 4-12 weeks after
mastectomy for Stage I or II breast cancer.
The tumour markers were measured in 57
women with Stage III or IV breast cancer
who were about to change treatment because
of clinically progressive disease. 31 of these
patients were followed up for 3-12 months
and venesection and assessment ofall measur-
able lesions repeated at 1-3-monthly inter-
vals. Patients receiving monthly chemo-
therapy were venesected immediately before
treatment. Assessment of all patients in-
cluded full medical history and examination,
chest X-ray, routine haematology and
measurement of serum urea, electrolyte,
aspartate transaminase, alkaline phosphatase,
5-nucleotidase and y-glutamyltranspeptidase
levels. Bony metastases were identified by
radiology and followed by repeated X-rays.
Brain scanning was performed when indicated
on clinical grounds. Clinical assessment and
tumour-marker measurements were per-
formed independently. Patients having
serious concomitant disease were excluded
from the study.
Regression of tumour was defined as at
least a 50% reduction in size of50% or more
of the measurable lesions, without pro-
gression of any and without the appearance
of new lesions. Patients with Stage I or II
breast cancer who remained disease-free for
at least 6 months after mastectomy were
classified as having tumour regression. Pro-
gression of disease was taken as a 50% or
greater increase in size or number of at least
50% of the measurable metastases, or the
development of metastases in a previously
uninvaded tissue, without regression of exist-
ing deposits.
Serum was frozen within 3 h ofvenesection
and stored at -40°C until assayed. Hapto-
globin estimations were made after 6-12
months of storage. Other markers were
measured within 1 month of venesection.
93 primary tumour specimens weighing 0-5-
2 g were obtained within 50 min of resection
of histologically proven primary breast
cancer. Bilateral malignant tumours were
removed during the same operation from one
patient and were processed separately.
Tumours were stored at -40°C in TED buffer
(10mM tris (pH 7-4), 1-0mM EDTA, 0-5mM
dithiothreitol). To prepare cytosol (soluble
extract) tumour was sliced finely, crushed in
liquid N2, homogenized in 5-10xw:v TED
buffer and centrifuged at 100,000 g for 1 h
(Cove et at., 1979). Cytosol was stored in
aliquots until assayed and results were ex-
pressed per gram wet wt of tumour.
Tumour marker measurement.-The milk
protein lactalbumin (Woods & Heath, 1977,
1978), carcinoembryonic antigen (CEA;
Booth et al., 1974), glycoprotein hormone cx
subunit (Cove et al., 1979), P human chorionic
gonadotrophin (HCG,B), calcitonin and
thyroid-stimulating hormone (TSH) were
measured by radioimmunoassay. Hapto-
globin and pregnancy-associated a2 glyco-
protein (PAG) were measured by rocket
immunoelectrophoresis (Laurell, 1972). Anti-
serum to HCGj3 subunit was raised in rabbits
to purified HCG/ (CR115 kindly donated by
R. E. Canfield) and used in a double-antibody
radioimmunoassay (Cove et al., 1979) in a
dilution of 1:100,000. The limit of detect-
ability (10% displacement) was 0-8 ,ug
HCGfl/l and the within- and between-assay
variations were 6% and 16% respectively.
Cross-reactivity at 50% displacement was:
HCG 6%, LH 5%, TSH 1% (LH,B, LHMu,
FSH, FSHP, FSHox, HCGoa less than 0-8%).
Calcitonin antiserum was raised in goats to
synthetic calcitonin M (Ciba-Geigy) and used
in a dilution of 1:40,000. TSH antiserum and
reference standard TSH were obtained from
N.I.A.M.D.D. Normal serum concentrations
of markers were determined from healthy
subjects (Table). The limits of detectability
of c subunit and CEA were 1-5 ,ug/l and 2-5
jug/l respectively.
RESULTS
Tumourproducts
CEA was detected in 41/60 (68%)
breast-tumour cytosols (Fig. 3) in a range
of 0-12-9-1 ,ug/g wet wt (mean= 1-65 ,ug/g
wet wt). Raised serum levels of CEA
(Fig. 1) were significantly more common
in either local or advanced disease than in
controls (P < 0-01, P < 0-001 respectively).
Serum CEA measurements were available
during 46 clinically evaluable changes of
tumour burden occurring in 40 patients
(Fig. 2). These data include reduction of
tumour burden by mastectomy in 25
patients. CEA was within thenormal range
in 20 patients before and after mastec-
tomy, and in 2 patients before and after
progression of advanced disease. In the
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TABLE.-The upper limits ofnormalfor the tumour-marker assays and the controls and
the criteria used to define the upper limits ofnormal
CE
La(
Ca SI
HC
Cal
TS]
Tumour Upper limit i
marker to normal co
A 15 ,tg/l
ctalbumin 0 4 ,ug/l
ubunit 4-6 Hg/l
6-3 pg/l
.,GP 2-4 tLg/l
2-7 ,ug/l
Icitonin 0-2 ug/l
H 4-0 mU/ll
Haptoglobin
PAG
230 std
serum
104 mg/l
introls Criterion
269 > 97.4% of controls
29*t limit of detectability
61*1 upper limit of normal range
23*§ mean+2 s.d.
20*t mean+2 s.d.
23*§ mean+ 2 s.d.
25 limit of detectability
100 upper limit of normal range
20 mean+2s.d.
20*t upper limit of normal range
Coefficient of
variation %
Within Between
assay
7
3
15
6
8 9
6 16
3 6
<3
<3
<3
<3
* Age-matched.
t Females.
: Premenopausal.
§ Postmenopausal.
remainder, CEA concentrations increased
(P< 0-01) with tumour progression, and
fell (P< 0 01) with tumour regression
(Wilcoxon paired rank test).
CEA change was appropriate to clinical
change in 20 instances and inappropriate
in 4. Of these 4, one patient had only
marginally elevated CEA concentrations
which did not change after mastectomy
(16-+17 ,tg/l) and 2 patients died from
disseminated disease within 3 months. In
all 3 patients who developed early (<6
months) recurrence ofbreast cancer, post-
operative CEA concentrations were raised
(CEA= 20, 22 and 31 ,ug/l). Serum and
cytosol CEA were measured in 36 patients.
Ten patients had elevated serum concen-
trations either preoperatively or at the
time of recurrence, and in all these CEA
was detectable at a higher concentration
in the primary tumour. In summary,
CEA is detectable in a large proportion of
primary breast carcinomas and is com-
monly found at raised levels in the serum
of patients with advanced disease.
Changes in raised serum CEA usually
reflect changes in tumour burden.
Lactalbumin was detected in 43% of 93
tumour cytosols (range= 0 8-50 ng/g wet
wt, mean= 9*6 ng/g wet wt). Lactalbumin
was detected in the serum of 12% of
patients with Stage I and II breast cancer
and in 23% ofthose with Stage III and IV
25w0.
250 .
100.
En
-a
:.
:E
40 -
<15
0
0
0
262
0
0
3.
0: I
0
0O
0-
@00
0
20
0
0*
6.
60
BREAST CANCER
CONTROLS Stage + II Stage III + IV
%> 15 pg/l 2.6 13 65
FIG. 1. Serum CEA concentrations in con-
trols and patients with local and advanced
breast cancer (O =patients with first re-
currence of tumour). The number of
samples in which CEA was < 15 Mzg/l is
given for each group.
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TUMOUR PROGRESSION TUMOUR REGRESSION
ON
/20+
I-C CONCORDMCE OF CEA AND CLINICAL CHANGE:- 46 -4 - -
Z CEA < pl
FiG. 2. Serum CEA concentrations before and after progression (n=17) or regression (n = 4) of
advanced breast cancer (0) and before and after resection of local breast cancer (0) (n=25).
disease, but in none of 29 age- and sex-
matched controls (Fig. 3).
as Subunit was found in 40% of 67
breast-tumour cytosols (range=8-5-1011
ng/g wet wt, mean=95-4 ng/g wet wt).
Raised serum concentrations were de-
tected in 10/104 patients with breast
cancer (range= 67-88 ,ug/l, mean= 19-2
pg/l). Two patients had markedly raised
serum concentrations (88 and 42 ,ug/l) and
both had advanced disease. In one patient,
symptomatic and partial radiological re-
mission was associated with a fall in serum
af subunit from 42 to 13 jug/l. The other
patient had exceptionally high concentra-
tions of ax subunit in both the primary
tumour (296ng/g wet wt) and aninfiltrated
axillary lymph node (101 ng/g wet wt).
HCGfl was detected in one cytosol
(6.8 ng/g wet wt) and one serum sample
(4.0 ,ug/l). Both samples also contained ax
subunit (18 ng/g wet wt and 42 ,ug/l
respectively).
Calcitonin was not detected in 22
tumour cytosols or in the sera from 77
patients with breast cancer. TSH was
undetected in 28 tumour cytosols. Raised
serum levels were found in 3/85 patients
with breast cancer (7.0, 22 and >50
mU/l). All 3 patients had Stage IV disease,
2 had received prior supraclavicular
irradiation and all had low or low-normal
serum thyroxine concentrations.
Acute-phase proteins
The mean serum haptoglobin levels
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40 .
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(a) SE
CEA Lactalb. 5 b CE j Sa Sub.
mastectomy, in advanced disease and in
ERUM - STAGE + controls. In 14 episodes of tumour re-
gression or progression in patients with
Stage IV disease, PAG changed appro-
Hapto. priately in 4, inappropriately in 2 and to
hCGP Calcft. TSH A an insignificant degree (<30%) in 8,
43 21 38 27 26 indicating that change of PAG concentra-
tion within the normal range is an un- rUM - STAGE 111 + IV *dv reliable guide of tumour burden.
401 Hapto.
201- Lactalb.
sub. TSH PAG
57 Si 53 51 56 47 55 41
CEA {c} CYTOSOL - PRIMARY TUMOUR
Lactaib. Sub.
hCGP Calcit. TSH
FiG. 3.-% of abnormal concentrations of
each marker in sera of patients with local
(a) and advanced (b) breast cancer. % of
cytosols with detectable concentrations of
each marker (c). The number of samples
measured is given in every case.
were higher in Stage III and IV breast
cancer (231 + 122% standard) than in
Stage I and II disease (P < 0.005) or in
controls (P < 0.05). The mean serum
haptoglobin in patients with local breast
cancer (123+72% standard) was no
greater than in controls (140+45%
standard) and was no lower after mastec-
tomy in the 19 patients tested (124 +
76% standard). In local disease, 2 of the 3
patients with raised haptoglobin de-
veloped metastatic disease within 3
months of mastectomy, and in advanced
disease haptoglobin was raised in 12/16
patients who died within 6 months of
venesection.
Serum PAG was raised in 1/28 patients
with local breast cancer and in 4/41 with
advanced disease. There was no significant
difference between serum PAG levels in
local breast cancer before and after
Markers in combination
CEA, lactalbumin and of subunit were
measured in the same cytosol prepara-
tions of 52 breast cancers (Fig. 4). One or
more of the markers was detectable in 44
(84%). CEA, lactalbumin, a subunit and
haptoglobin were each measured in the
same serum samples from 21 patients with
local and 53 patients with advanced breast
cancer. One or more of the markers was
greater than the upper limits ofnormal in
33% and 81% patients respectively. Many
abnormal levels were just above the nor-
mal range, and marker concentrations
greater than twice the upper limits of
normal were found in 19% of local and
54% of advanced cancer patients. There
was no significant association or dissocia-
tion between the detection of one marker
and another in serum or cytosol. Some
patients had several markers detectable
in cytosol or abnormal in serum. In one
patient who had a symptomatic and
partial radiological response to adrenal-
ectomy, preoperatively raised serum CEA
(133 jug/l), lactalbumin (0.5 ,ug/l), cx sub-
unit (42 Itg/l) and HCG/3 (4.0 ,ug/l) fell to
63, < 0 4, 13 and 2-9 jtg/l respectively. In
another patient with disseminated disease,
serum levels of lactalbumin, CEA and cx
subunit were raised and all 3 markers were
detected in cytosols from the primary
tumour and an infiltrated axillary node.
DISCUSSION
CEA fulfils the initial requirements of a
satisfactory tumour marker. Its levels are
frequently raised, often to a considerable
degree, and it is more commonly raised in
advanced than in local disease. Previous
60
401
201
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SERA
MARKER DETECTABLE > NORMAL > NORMAL NORMAL
CONC.
FIG. 4.-Cumulative % of markers detectable in cytosols (52 tumours) and abnormal in sera from
patients with local (n = 21) and advanced (n = 53) breast cancer.
studies report similar abnormalities of
serum CEA in local and in advanced breast
cancer, but whereas some (Steward et al.,
1974; Tormey et al., 1977) found changes
in CEA reflected progression or regression
of disease in individual patients, Chu &
Nemoto (1973) concluded that CEA was
an unreliable guide to tumour burden. In
follow-up of individual patients we find
that changes in abnormal serum CEA
levels are concordant with clinical change
in tumour burden in 83% of cases.
Possible exceptions are marginally raised
CEA levels and CEA measurements in
pre-terminal patients. A terminal fall in
CEA has been noted in carcinoma of the
colon (Ravry et al., 1974). An accurate
lead-in time for CEA could not be esti-
mated from the present study but the
CEA level was raised in 7/12 patients at
the time of first occurrence and in 5/12
cases of advanced disease CEA change
appeared to predict clinical change by
1-3 months. Serial CEA measurements in
postmastectomy patients may allow early
recognition of recurrent disease.
Arterio-venous differences provide the
best evidence of tumour secretion of a
marker, but measurements in tumour ex-
tracts are a more practicable alternative
for breast tumours. We have found that
68% of primary breast tumours contain
detectable CEA in concentrations greater
than are found in serum. It is ofparticular
interest that the proportion of CEA-
positive tumours is similar to the propor-
tion ofStage III and IV patients who have
raised serum levels of CEA. It is possible
that metastases secreting CEA are only
derived from CEA-positive primary
tumours. If this were the case, screening
patients for raised serum CEA or for CEA-
positive metastases by radioisotopic
methods (Goldenberg et al., 1978) could
be limited to those with CEA-positive
primary tumours.
The milk proteins casein and lact-
albumin (Woods et al., 1979) have been
examined as "appropriate products" in
breast cancer. Perhaps because of the
heterogeneity of casein, wide variation in
abnormal levels is found (Monaco et al.,
1979; Hendrick & Franchimont, 1974;
Zangerle, 1976). We find lactalbumin in
I- CYTOSOLS --
80
60
40
40
80
C.)
20
0
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43% of tumour cytosols, and serum lact-
albumin is more commonly abnormal in
advanced than in local disease, suggesting
a relationship to tumour burden. of sub-
unit is detectable in 4000 of tumour ex-
tracts, but rarely appears in the serum in
concentrations high enough to be of any
clinical value (Cove et al., 1979).
We find no evidence to support sugges-
tions that HCG3 (Franchimont et al.,
1976; Sheth et al., 1977) or calcitonin
(Coombes et al., 1974) are commonly pro-
duced by breast tumours, or could be used
as tumour markers in breast cancer. We
found no definite cases ofectopic secretion
of TSH, and high serum levels of TSH
were probably due to hypothyroidism. We
are unable to confirm the suggestion of a
common thyroid disorder in breast cancer
(Mittra & Haywood, 1974).
Raised serum levels of acute-phase
proteins have been described in associa-
tionwith avarietyofcarcinomas (Coombes
et al., 1977; Bradwell et al., 1977). In the
present study, serum PAG was more
commonly raised in patients with ad-
vanced than local disease, suggesting a
relationship to tumour burden in a few
individuals. Anderson et al. (1976) and
Stimson (1975) reported that changes of
PAG within the normal range are of pre-
dictive value in breast cancer. Our results
show that changes of PAG within the
normal range are a most unreliable guide
to tumour burden and cannot be used as
the basis for therapy.
Serum haptoglobin levels were more
commonly raised in patients with ad-
vanced (40%) than those with local (11%)
breast cancer and appeared to be associat-
ed with rapidly progressive disease.
However, the use of acute-phase proteins
in breast cancer is likely to be limited
because, irrespective of change in tumour
burden, they may be affected by the inter-
ference of treatment with host responsive-
ness (e.g. surgery, radiotherapy and
chemotherapy).
In combination a raised level of one or
more markers was detected in 3400
patients with local breast cancer and 810%
with advanced disease. Measurement of
additional tumour-indexing substances
(Tormey et al., 1975; Coombes et al., 1977)
might be expected to increase the propor-
tion of patients with an abnormal level
but would also increase the number of
false-positive results. Markers of value
in clinical management are usually present
in serum in concentrations many times the
normal (Bagshawe, 1974; Rosen et al.,
1975) whereas the abnormal levels re-
ported here are frequently less than twice,
and rarely more than 10 times the upper
limits of normal, and such abnormalities
are unlikely to be sensitive guides to
tumour burden. Although CEA is the best
marker of breast cancer in this and other
studies (Franchimont et al., 1976; Tormey
et al., 1975; Coombes et al., 1977) it is only
abnormal in the serum of about 13% of
patients with readily palpable primary
breast tumours (many of which will have
already metastasized); this indicates that
even CEA is a crude index of tumour
burden.
The use of a combination of markers
might provide some prediction of clinical
change in advanced disease and assist
patient assessment during drug trials, but
it is unlikely to achieve any direct im-
provement in mortality or morbidity.
The relative insensitivity of the current
markers is also indicated by the small pro-
portion of patients with local disease who
had abnormal concentrations. New and
more sensitive tumour markers (probably
tumour products) are required if minimal
residual disease after mastectomy is to be
detected. A theoretical alternative is the
in vivo application of methods used in cell
culture for stimulating tumour marker
synthesis and release (Grieve et al., 1978;
Lieblich et al. 1976).
We have found that CEA, lactalbumin
and ax subunit are commonly detectable in
breast-cancer cytosols. Our results confirm
what might be expected, namely that the
tumour products most frequently detected
in cytosols (CEA, lactalbumin and of sub-
unit) are most commonly abnormal in
patients' sera, and that tumour concen-
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trations are greater than serum concen-
trations. Further information is required
to define the relationship between tumour
and serum concentration of markers, and
between marker synthesis in primary and
secondary tumours.
The identification of markers within
primary tumours could become clinically
important for several reasons. Firstly, the
screening of patients for metastatic
disease either by serum measurements of
markers or by radioisotopic techniques
might be best limited to patients with
marker-positive primary tumours. Second-
ly, the presence of a marker may be
related to a biological characteristic of
clinical significance such as lactalbumin
and hormonal responsiveness (Woods etal.,
1977) and HCG and prognosis (Horne et
al., 1976). Thirdly, the synthesis oftumour
products by tumours grown in cell or
tissue culture or transplanted into "nude"
(immunosuppressed) mice is important in
research into tumour differentiation and
proliferation, and may be of clinical value
if such methods are used to test tumour
sensitivity to therapeutic regimes. The
identification of 3 tumour products de-
tectable in a total of 84% primary breast
tumours may improve our understanding
ofbreast cancer and ultimately aid patient
management.
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